News
"I'm not going to second-guess myself."Wegovy belongs to a pricey class of drugs called GLP-1s (short for glucagon-like ...
The Most Favored Nation order is unlikely to deliver broad, sustained savings without triggering legal challenges, ...
StockStory.org on MSN1d
AGL Q1 Earnings Call: Membership Declines, Technology Investments, and Cautious Outlook for 2025Healthcare services company Agilon Health (NYSE:AGL) reported Q1 CY2025 results , but sales fell by 4.5% year on year to $1.53 billion. The company expects next quarter’s revenue to be around $1.47 ...
UnitedHealth Group faces real PBM reform risks, but legal paths, financials, and market pricing suggest opportunity in ...
While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, ...
A new analysis looked at estimated out-of-pocket costs for etanercept, ustekinumab, and ibrutinib, specialty drugs that often ...
The executive order would require other countries to pay more for medications so that Americans could pay less. But experts ...
FRIDAY, May 16, 2025 (HealthDay News) — Low-income Medicare beneficiaries are more likely to die if they lose access to ...
Under the Medicare Drug Price Negotiation Program, the HHS secretary negotiates directly with manufacturers on the prices ...
President Donald Trump signed an Executive Order (EO) titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” aimed ...
The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.
New government data shows the pace of inflation has subsided from pandemic-era highs. Social Security beneficiaries may see a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results